Table 2 Topical Tacrolimus in anterior segment disorders

CAU

20/Taddio et al.

6 (3)

Solution 0.1%

3 times

Case series

Scleritis

16/Miyazaki et al.

2 (2)

Ointment 0.02%

1–4 times

Retrospective

Scleritis

31/Lee et al.

4 (4)

Ointment 0.02%

1–4 times

Retrospective

GVHD

32/Jung et al.

24 (13)

Ointment 0.02%

1–2 times

Retrospective

GVHD

33/Tam et al.

2 (1)

Ointment 0.03%

2 times

Case report

GVHD

34/Ryu et al.

14 (7)

Ointment 0.02%

2 times

Prospective

GVHD

35/Abud et al.

48 (24)

Suspension 0.05%

2 times

Prospective

OCP

39/Hall et al.

2 (1)

Ointment 0.03%

once daily

Case report

OCP

40/Michel et al.

2 (1)

Ointment 0.03%

once daily

Case report

OCP

31/Lee et al.

2 (1)

Ointment 0.02%

1–3 times

Retrospective

SJS

31/Lee et al.

11 (5)

Ointment 0.02%

1–3 times

Retrospective

SLK

44/Kymionis et al.

4 (2)

Ointment0.03%

2 times

Case report

AK

47/Ghanem et al.

10 (7)

Suspension 0.03%

2 times

Prospective

AK

48/Levinger et al.

11 (11)

Ointment 0.03%

2 times

Prospective

Dry Eye

50/Moscovici et al.

48 (42)

Suspension 0.03%

2 times

Prospective

PKC

51/Kymionis et al.

2 (2)

Ointment 0.03%

2 times

Case report

PKP

59/Dhaliwal et al.

4 (4)

Ointment 0.03%

2 times

Case series

PKP

60/Magalhaes et al.

36 n

Suspension 0.03%

2 times

Retrospective

PKP

61/Reinhard et al.

20 20)

Solution 0.06%

3 times

Prospective